Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022
Related reading
How GSK is rebuilding its cancer business
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
AstraZeneca revives Cambridge investment after UK agrees to pay more for drugs
Resumption of £300mn in UK projects is a result of trade deal with US that aims to increase medicines spending
Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences
Transaction continues a frenzy of M&A activity this year in the healthcare sector
Merck’s record cancer drug sales power earnings growth
Quarterly proceeds from Keytruda top $8bn for first time